newsfilter
← Latest News
GlobeNewswire·

Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Following recent transactions and cost-cutting efforts, Sol-Gel's cash runway is expected to extend into the first quarter of 2026Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with over 30 clinical sites